Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 8, 2008, Pages 984-993

  Peyrin Biroulet, L ^a   Cadranel, J F ^b   Nousbaum, J B ^c   Oussalah, A ^a   Seddik, M ^b   Canva, V ^d   Cortot, A ^d   Sogni, P ^e   Gueant, J L ^a   Bigard, M A ^a   Roblin, X ^f   Bronowicki, J P ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b CENTRE HOSPITALIER LAENNEC   (France)

^c SERVICE DE RHUMATOLOGIE   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e University Hospital Cochin ^*  (France)

^f UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; DRUG METABOLITE; HEMOGLOBIN; INOSINATE DEHYDROGENASE INHIBITOR; NUCLEOTIDE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ADULT; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL PRACTICE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; MALE; NEUTROPHIL COUNT; PANCYTOPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; ANTIVIRAL AGENTS; AZATHIOPRINE; DRUG INTERACTIONS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PANCYTOPENIA; PLATELET COUNT; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS;

EID: 52149083268     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03812.x     Document Type: Article

References (30)

1. Winter JW, Gaffney D, Shapiro D, et al. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2007 25 : 1069 77.
2. Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther 2006 24 : 715 29.
3. Gish RG. Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother 2006 57 : 8 13.
4. Hindorf U, Lindqvist M, Peterson C, et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 2006 55 : 1423 31.
5. Gilissen LP, Derijks LJ, Verhoeven HM, et al. Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease. Dig Liver Dis 2007 39 : 182 6.
6. Roblin X, Serre-Debeauvais F, Phelip JM, et al. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine. Aliment Pharmacol Ther 2005 21 : 829 39.
7. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007 5 : 209 14.
8. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980 32 : 651 62.
9. Dervieux T, Boulieu R. Identification of 6-methylmercaptopurine derivative formed during acid hydrolysis of thiopurine nucleotides in erythrocytes, using liquid chromatography-mass spectrometry, infrared spectroscopy, and nuclear magnetic resonance assay. Clin Chem 1998 44 : 2511 5.
10. Thevenot T, Mathurin P, Moussalli J, et al. Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin. J Viral Hepat 1997 4 : 243 53.
11. Haglund S, Taipalensuu J, Peterson C, Almer S. IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol 2008 65 : 69 77.
12. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006 355 : 2444 51.
13. Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn WJ. Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology 1999 116 : 1505 6.
14. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000 118 : 1025 30.
15. de Boer NK, van Bodegraven AA, de Graaf P, van der Hulst RW, Zoetekouw L, van Kuilenburg AB. Paradoxical elevated thiopurine S-methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age. Ther Drug Monit 2008 30 : 390 3.
16. Schaeffeler E, Eichelbaum M, Reinisch W, Zanger UM, Schwab M. Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) - association with decreased enzyme function. Hum Mutat 2006 27 : 976.
17. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002 122 : 904 15.
18. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006 130 : 1047 53.
19. Roberts RL, Gearry RB, Barclay ML, Kennedy MA. IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics J 2007 7 : 312 7.
20. Biancone L, Pavia M, Del Vecchio Blanco G, et al. Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis 2001 7 : 287 94.
21. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007 132 : 52 65.
22. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005 54 : 237 41.
23. Kanwal F, Hoang T, Spiegel BM, et al. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology 2007 46 : 1741 9.
24. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006 354 : 54 66.
25. Remuzzi G, Lesti M, Gotti E, et al. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 2004 364 : 503 12.
26. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007 132 : 1979 98.
27. Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006 12 : 1192 204.
28. Ansari A, Aslam Z, De Sica A, et al. The influence of xanthine oxidase on thiopurine metabolism in Crohn's disease. Aliment Pharmacol Ther 2008 doi:.
29. Rahhal RM, Bishop WP. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008 in press.
30. de Boer NK, Wong DR, Jharap B, et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol 2007 102 : 2747 53.